Logo image of SANG

SANGOMA TECHNOLOGIES CORP (SANG) Stock Fundamental Analysis

USA - NASDAQ:SANG - CA80100R4089 - Common Stock

5.2 USD
+0.18 (+3.59%)
Last: 11/12/2025, 10:59:14 AM
Fundamental Rating

3

Overall SANG gets a fundamental rating of 3 out of 10. We evaluated SANG against 48 industry peers in the Communications Equipment industry. SANG has a bad profitability rating. Also its financial health evaluation is rather negative. SANG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

SANG had negative earnings in the past year.
SANG had a positive operating cash flow in the past year.
SANG had negative earnings in 4 of the past 5 years.
In the past 5 years SANG always reported a positive cash flow from operatings.
SANG Yearly Net Income VS EBIT VS OCF VS FCFSANG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

SANG's Return On Assets of -1.45% is in line compared to the rest of the industry. SANG outperforms 45.83% of its industry peers.
SANG has a Return On Equity (-1.97%) which is in line with its industry peers.
Industry RankSector Rank
ROA -1.45%
ROE -1.97%
ROIC N/A
ROA(3y)-3.39%
ROA(5y)-6.47%
ROE(3y)-5.4%
ROE(5y)-10.77%
ROIC(3y)N/A
ROIC(5y)N/A
SANG Yearly ROA, ROE, ROICSANG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30

1.3 Margins

SANG's Gross Margin of 68.34% is amongst the best of the industry. SANG outperforms 93.75% of its industry peers.
In the last couple of years the Gross Margin of SANG has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for SANG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.76%
GM growth 5Y1.11%
SANG Yearly Profit, Operating, Gross MarginsSANG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

3

2. Health

2.1 Basic Checks

SANG does not have a ROIC to compare to the WACC, probably because it is not profitable.
SANG has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, SANG has more shares outstanding
The debt/assets ratio for SANG has been reduced compared to a year ago.
SANG Yearly Shares OutstandingSANG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
SANG Yearly Total Debt VS Total AssetsSANG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

SANG has an Altman-Z score of 1.14. This is a bad value and indicates that SANG is not financially healthy and even has some risk of bankruptcy.
SANG's Altman-Z score of 1.14 is in line compared to the rest of the industry. SANG outperforms 47.92% of its industry peers.
The Debt to FCF ratio of SANG is 1.70, which is an excellent value as it means it would take SANG, only 1.70 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 1.70, SANG is doing good in the industry, outperforming 70.83% of the companies in the same industry.
SANG has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
SANG has a Debt to Equity ratio of 0.13. This is comparable to the rest of the industry: SANG outperforms 52.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 1.7
Altman-Z 1.14
ROIC/WACCN/A
WACC8.18%
SANG Yearly LT Debt VS Equity VS FCFSANG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.3 Liquidity

SANG has a Current Ratio of 0.86. This is a bad value and indicates that SANG is not financially healthy enough and could expect problems in meeting its short term obligations.
SANG has a worse Current ratio (0.86) than 93.75% of its industry peers.
A Quick Ratio of 0.70 indicates that SANG may have some problems paying its short term obligations.
SANG's Quick ratio of 0.70 is on the low side compared to the rest of the industry. SANG is outperformed by 91.67% of its industry peers.
Industry RankSector Rank
Current Ratio 0.86
Quick Ratio 0.7
SANG Yearly Current Assets VS Current LiabilitesSANG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

3

3. Growth

3.1 Past

SANG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.00%, which is quite impressive.
SANG shows a decrease in Revenue. In the last year, the revenue decreased by -4.28%.
SANG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.31% yearly.
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-4.28%
Revenue growth 3Y1.79%
Revenue growth 5Y19.31%
Sales Q2Q%-15.51%

3.2 Future

The Earnings Per Share is expected to grow by 63.09% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -3.99% on average over the next years.
EPS Next Y19.2%
EPS Next 2Y63.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-12.77%
Revenue Next 2Y-3.99%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SANG Yearly Revenue VS EstimatesSANG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
SANG Yearly EPS VS EstimatesSANG Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -1 -2 -3

3

4. Valuation

4.1 Price/Earnings Ratio

SANG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 52.54, the valuation of SANG can be described as expensive.
Based on the Price/Forward Earnings ratio, SANG is valued a bit more expensive than 64.58% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 33.72, SANG is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 52.54
SANG Price Earnings VS Forward Price EarningsSANG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SANG is valued cheaply inside the industry as 97.92% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, SANG is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 5.25
EV/EBITDA 4.79
SANG Per share dataSANG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SANG does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as SANG's earnings are expected to grow with 63.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y63.09%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

SANG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

SANGOMA TECHNOLOGIES CORP

NASDAQ:SANG (11/12/2025, 10:59:14 AM)

5.2

+0.18 (+3.59%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryCommunications Equipment
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)02-03 2026-02-03
Inst Owners34.91%
Inst Owner Change-0.51%
Ins Owners27.21%
Ins Owner ChangeN/A
Market Cap172.90M
Revenue(TTM)236.69M
Net Income(TTM)-5.01M
Analysts80
Price Target7.77 (49.42%)
Short Float %0.09%
Short Ratio2.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)281.52%
Min EPS beat(2)-32.01%
Max EPS beat(2)595.05%
EPS beat(4)1
Avg EPS beat(4)89.5%
Min EPS beat(4)-197.03%
Max EPS beat(4)595.05%
EPS beat(8)2
Avg EPS beat(8)2.25%
EPS beat(12)5
Avg EPS beat(12)12.48%
EPS beat(16)6
Avg EPS beat(16)-258.64%
Revenue beat(2)1
Avg Revenue beat(2)-1.04%
Min Revenue beat(2)-2.42%
Max Revenue beat(2)0.34%
Revenue beat(4)1
Avg Revenue beat(4)-3.25%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)0.34%
Revenue beat(8)2
Avg Revenue beat(8)-2.22%
Revenue beat(12)3
Avg Revenue beat(12)-2.89%
Revenue beat(16)7
Avg Revenue beat(16)0.74%
PT rev (1m)2.21%
PT rev (3m)-0.4%
EPS NQ rev (1m)-72.31%
EPS NQ rev (3m)-86.67%
EPS NY rev (1m)-349.94%
EPS NY rev (3m)-185.71%
Revenue NQ rev (1m)-5.6%
Revenue NQ rev (3m)-14.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-14.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 52.54
P/S 0.73
P/FCF 5.25
P/OCF 4.14
P/B 0.68
P/tB N/A
EV/EBITDA 4.79
EPS(TTM)-0.15
EYN/A
EPS(NY)0.1
Fwd EY1.9%
FCF(TTM)0.99
FCFY19.06%
OCF(TTM)1.26
OCFY24.17%
SpS7.12
BVpS7.64
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.45%
ROE -1.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.34%
FCFM 13.92%
ROA(3y)-3.39%
ROA(5y)-6.47%
ROE(3y)-5.4%
ROE(5y)-10.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.76%
GM growth 5Y1.11%
F-Score6
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 1.7
Debt/EBITDA 0.78
Cap/Depr 19.62%
Cap/Sales 3.73%
Interest Coverage N/A
Cash Conversion 95.46%
Profit Quality N/A
Current Ratio 0.86
Quick Ratio 0.7
Altman-Z 1.14
F-Score6
WACC8.18%
ROIC/WACCN/A
Cap/Depr(3y)22.92%
Cap/Depr(5y)19.53%
Cap/Sales(3y)4.2%
Cap/Sales(5y)3.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y19.2%
EPS Next 2Y63.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.28%
Revenue growth 3Y1.79%
Revenue growth 5Y19.31%
Sales Q2Q%-15.51%
Revenue Next Year-12.77%
Revenue Next 2Y-3.99%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2383.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.16%
FCF growth 3Y27.36%
FCF growth 5Y36.51%
OCF growth 1Y-5.56%
OCF growth 3Y25.66%
OCF growth 5Y36.31%

SANGOMA TECHNOLOGIES CORP / SANG FAQ

What is the fundamental rating for SANG stock?

ChartMill assigns a fundamental rating of 3 / 10 to SANG.


Can you provide the valuation status for SANGOMA TECHNOLOGIES CORP?

ChartMill assigns a valuation rating of 3 / 10 to SANGOMA TECHNOLOGIES CORP (SANG). This can be considered as Overvalued.


What is the profitability of SANG stock?

SANGOMA TECHNOLOGIES CORP (SANG) has a profitability rating of 3 / 10.


Can you provide the financial health for SANG stock?

The financial health rating of SANGOMA TECHNOLOGIES CORP (SANG) is 3 / 10.